HK1212617A1 - 白癜風的治療 - Google Patents
白癜風的治療Info
- Publication number
- HK1212617A1 HK1212617A1 HK16100610.2A HK16100610A HK1212617A1 HK 1212617 A1 HK1212617 A1 HK 1212617A1 HK 16100610 A HK16100610 A HK 16100610A HK 1212617 A1 HK1212617 A1 HK 1212617A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vitiligo
- treatment
- Prior art date
Links
- 206010047642 Vitiligo Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261700153P | 2012-09-12 | 2012-09-12 | |
PCT/US2013/059294 WO2014043257A1 (en) | 2012-09-12 | 2013-09-11 | Treatment for vitiligo |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212617A1 true HK1212617A1 (zh) | 2016-06-17 |
Family
ID=49226574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100610.2A HK1212617A1 (zh) | 2012-09-12 | 2016-01-20 | 白癜風的治療 |
Country Status (6)
Country | Link |
---|---|
US (2) | US9034881B2 (zh) |
EP (1) | EP2895172B1 (zh) |
JP (2) | JP2015528501A (zh) |
CA (1) | CA2884710A1 (zh) |
HK (1) | HK1212617A1 (zh) |
WO (1) | WO2014043257A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP2895172B1 (en) * | 2012-09-12 | 2019-02-06 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
RU2018106663A (ru) * | 2015-07-24 | 2019-08-26 | Глэксо Груп Лимитед | Лечение витилиго |
EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Anhydrous compositions of MTOR inhibitors and method of use |
WO2019040706A1 (en) * | 2017-08-24 | 2019-02-28 | Aclaris Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING VITILIGO |
JP2021518332A (ja) * | 2018-03-14 | 2021-08-02 | ポビバ コーポレーションPoviva Corp. | 親油性の活性薬剤の経皮及び/又は皮膚送達 |
JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物および使用方法 |
US11123390B2 (en) * | 2018-09-18 | 2021-09-21 | Kuwait University | Method for treating vitiligo |
MX2023006638A (es) * | 2020-12-04 | 2023-08-22 | Incyte Corp | Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel. |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US296006A (en) | 1884-04-01 | John hoefleb | ||
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
USD296006S (en) | 1985-06-20 | 1988-05-31 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patch for administering drugs to the skin |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
WO2007070872A1 (en) | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
BRPI0715418A2 (pt) * | 2006-07-21 | 2013-03-26 | Novartis Ag | compostos de 2,4-di(arilaminio)-pirimidina-5-carboxamida como inibidores de cinases jak |
CA2673125C (en) * | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
AU2010281404A1 (en) * | 2009-07-28 | 2012-02-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
BR112012019511A2 (pt) * | 2010-02-05 | 2016-08-23 | Pfizer | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. |
BR112013023052A2 (pt) * | 2011-03-10 | 2017-07-25 | Rigel Pharmaceuticals Inc | métodos para tratar lúpus cutâneo, e um indivíduo, kit, e, uso de um composto |
MX345571B (es) * | 2012-07-09 | 2017-02-03 | Vid Scale Inc | Decodificacion y emision en tiempo real de video sensibles a la energia. |
EP2895172B1 (en) * | 2012-09-12 | 2019-02-06 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
-
2013
- 2013-09-11 EP EP13765904.1A patent/EP2895172B1/en not_active Not-in-force
- 2013-09-11 WO PCT/US2013/059294 patent/WO2014043257A1/en active Application Filing
- 2013-09-11 CA CA2884710A patent/CA2884710A1/en not_active Abandoned
- 2013-09-11 JP JP2015532024A patent/JP2015528501A/ja not_active Withdrawn
- 2013-09-12 US US14/025,609 patent/US9034881B2/en active Active
-
2015
- 2015-05-18 US US14/715,322 patent/US9730930B2/en active Active
-
2016
- 2016-01-20 HK HK16100610.2A patent/HK1212617A1/zh not_active IP Right Cessation
-
2018
- 2018-03-29 JP JP2018063403A patent/JP2018115205A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2895172B1 (en) | 2019-02-06 |
US20140073659A1 (en) | 2014-03-13 |
JP2018115205A (ja) | 2018-07-26 |
WO2014043257A1 (en) | 2014-03-20 |
US9730930B2 (en) | 2017-08-15 |
EP2895172A1 (en) | 2015-07-22 |
US20150246039A1 (en) | 2015-09-03 |
JP2015528501A (ja) | 2015-09-28 |
US9034881B2 (en) | 2015-05-19 |
CA2884710A1 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267242B (en) | Cancer treatment | |
EP2903610A4 (en) | CANCER TREATMENTS | |
EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
HK1212617A1 (zh) | 白癜風的治療 | |
HK1210023A1 (zh) | 癌症治療 | |
GB201207305D0 (en) | Therapy | |
EP2863939A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
HK1209040A1 (zh) | 用於治療前庭毒性的方法 | |
ZA201308117B (en) | Avian-based treatment | |
GB201222563D0 (en) | Cancer treatment | |
GB201211135D0 (en) | Treatment | |
GB201208690D0 (en) | Treatment | |
GB201212604D0 (en) | New treatment | |
GB201205449D0 (en) | Treatment process | |
GB201111247D0 (en) | Treatment | |
GB201109119D0 (en) | Treatment | |
GB201102284D0 (en) | Treatment | |
GB201102268D0 (en) | Treatment | |
GB201102273D0 (en) | Treatment | |
GB201102271D0 (en) | Treatment | |
GB201102274D0 (en) | Treatment | |
GB201102275D0 (en) | Treatment | |
GB201102288D0 (en) | Treatment | |
GB201102269D0 (en) | Treatment | |
GB201102265D0 (en) | Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230909 |